This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 23, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updated that the Company's 2012 Annual Shareholder Meeting will be held at
130 w. 42 nd Street, Suite 1050 (on the 10 th Floor, conference room of the law office of Hunter Taubman Weiss LLP), New York, NY 10036 on Wednesday, May 8, 2013, at 10:00 am (ET), relocated from the previous meeting site at 17 State Street,
New York, NY 10004. You may also use another entrance of the same building at 135 w. 41st Street. When you arrive on the 10
th Floor, please look for signs of "Tianyin Pharmaceutical Co., Inc. Annual Meeting." You could also attend the meeting telephonically by dialing 712-432-0080 (access code: 512917).
TPI's Board of Directors had established Monday, March 11, 2013, as the record date for determining the stockholders entitled to vote at the Annual Meeting.
Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of
China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.